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Objective. The Miami Heart Study (MiHeart) at Baptist Health South Florida is an ongoing, community-
based, prospective cohort study aimed at characterizing the prevalence, characteristics, and prognostic 
value of diverse markers of early subclinical coronary atherosclerosis and of various potential 
demographic, psychosocial, and metabolic risk factors. We present the study objectives, detailed 
research methods, and preliminary baseline results of MiHeart.  
Methods. MiHeart enrolled 2,459 middle-aged male and female participants from the general 
population of the Greater Miami Area. Enrollment occurred between May 2015 and September 2018 
and was restricted to participants aged 40–65 years free of clinical cardiovascular disease (CVD). The 
baseline examination included assessment of demographics, lifestyles, medical history, and a detailed 
evaluation of psychosocial characteristics; a comprehensive physical exam; measurement of multiple 
blood biomarkers including measures of inflammation, advanced lipid testing, and genomics; 
assessment of subclinical coronary atherosclerotic plaque and vascular function using coronary 
computed tomography angiography, the coronary artery calcium score, carotid intima-media thickness, 
pulse wave velocity, and peripheral arterial tonometry; and other tests including 12-lead 
electrocardiography and assessment of pulmonary function. Blood samples were biobanked to facilitate 
future ancillary research.  
Results. MiHeart enrolled 1,261 men (51.3%) and 1,198 women (48.7%). Mean age was 53 years, 85.6% 
participants were White and 47.4% were of Hispanic/Latino ethnicity. The study included 7% individuals 
with diabetes, 33% with hypertension, and 15% used statin therapy at baseline. Overweight or obese 
participants comprised 72% of the population and 3% were smokers. Median 10-year estimated 
atherosclerotic CVD risk using the Pooled Cohort Equations was 4%. 
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Conclusion. MiHeart will provide important, novel insights into the pathophysiology of early subclinical 
atherosclerosis and further our understanding of its role in the genesis of clinical CVD. The study findings 
will have important implications, further refining current cardiovascular prevention paradigms and risk 
assessment and management aproaches moving forward. 
 
KEYWORDS 
atherosclerosis; cardiovascular disease; cohort studies; coronary computed tomography; epidemiology; 
Hispanic/Latino; populations; primary prevention 
 
ABBREVIATIONS AND ACRONYMS 
BHSF  Baptist Health South Florida 
CAC  coronary artery calcium 
CCTA  coronary computed tomography angiography 
CIMT  carotid intima media thickness 
CT  computed tomography 
CVD  cardiovascular disease 
EDTA  ethylenediaminetetraacetic acid 
IRB  Institutional Review Board 
MESA  Multi-Ethnic Study of Atherosclerosis 
MiHeart Miami Heart Study 




 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and 
accounts for a large share of total health care expenditure.1–3 While CVD risk assessment in general has 
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been traditionally guided by risk estimates derived from scores combining traditional risk factors, there 
is a growing body of evidence showing that such an approach lacks sufficient accuracy in predicting risk 
of future events among asymptomatic individuals.4–9 Consequently, in recent years there has been a 
considerable interest in a paradigm change in the approach to primary CVD prevention, expanding the 
focus from surrogate risk factors alone to also assess the disease process itself.10,11 In this regard, 
detection of atherosclerosis via subclinical disease assessment provides information about the actual 
disease burden, and as such, performs better than surrogate biomarkers.4,10–17 
A robust, low-radiation, relatively inexpensive marker of atherosclerotic coronary artery disease, 
the coronary artery calcium (CAC) score is now a guideline-endorsed test for further risk assessment.11 
CAC has consistently shown powerful predictive value beyond conventional cardiac risk factors in 
asymptomatic individuals in multiple population-based cohorts.4,12–17 Although CAC is an excellent 
marker of underlying coronary atherosclerosis, it does not capture the whole spectrum of plaque 
morphology and plaque burden.18,19 Indeed, the coronary calcified plaque burden has been shown to 
represent only 20% of the total plaque burden, as coronary atherosclerosis is mostly lipid-laden or 
fibrous.20,21  
In addition, significant gaps remain in scientific knowledge with regards to the relationship 
between multiple lifestyle factors, genetic and metabolic risk factors and biomarkers, and early plaque 
biology. The analysis of these associations has so far been hampered by lack of accurate and well-
defined atherosclerotic phenotypes in clinical settings in asymptomatic populations. Coronary computed 
tomography angiography (CCTA) is a noninvasive technique for the evaluation of the coronary anatomy, 
stenosis, and the characterization of atherosclerotic plaques.18,22–27 Until now, the presence, burden and 
differential architectural features of atherosclerotic plaque in the coronary arteries has remained 
unexplored in large populations of asymptomatic individuals. This is particularly true in populations of 
young to middle-aged asymptomatic individuals, who may at priority be considered at low risk for 
cardiovascular events. In such a population, CCTA may allow for the assessment of the early stages of 
coronary atherosclerosis, facilitating the identification of its key determinants.  
The Miami Heart Study (MiHeart) at Baptist Health South Florida (BHSF) is an ongoing, 
community-based, prospective cohort study of individuals from the general population free of clinical 
CVD. MiHeart is aimed at characterizing the presence, features, architecture as well as prognostic ability 
of earliest diverse markers of subclinical coronary atherosclerotic disease in a population-based cohort 
of young- and middle-aged men and women free of established CVD; and for this purpose, all 
participants underwent CCTA at the study baseline. In this article we describe the underlying rationale, 
study objectives, methods used, and preliminary baseline results of MiHeart. 
 
Study Objectives 
 The primary objectives of MiHeart are to: 1) assess and characterize the presence and severity 
of subclinical CVD burden among middle-aged asymptomatic individuals; and 2) determine relationships 
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of traditional risk factors, lifestyle and behavioral factors as well and biomarkers (traditional and novel) 
related to presence and burden of subclinical CVD among middle-aged asymptomatic individuals. 
The secondary study objectives are to: 3) determine the interplay of risk factors (traditional, 
lifestyle, biomarkers) and early markers of subclinical CVD with the development of clinical CVD; 4) 
determine relationships of traditional risk factors, lifestyle and behavioral factors as well and biomarkers 
(traditional and novel) related to presence and burden of subclinical CVD among middle-aged 
asymptomatic individuals; and 5) develop population-based methods, suitable for application in future 
screening and intervention studies, for characterizing cardiovascular risk among middle-aged 
asymptomatic persons as well cost effectiveness for such paradigms in appropriately resource allocation 
for early CVD management. 
 
Methods 
Study Design and Population 
MiHeart (clinicaltrials.gov identifier NCT0250845428) is an observational, community-based, 
longitudinal, prospective cohort study that included 2,459 middle-aged male and female participants 
from the population of the Greater Miami Area (Figure). Study recruitment was based on volunteer 
participation. Since the study is primarily concerned with the determinants and natural history of 
subclinical CVD, the age range of the study population was set between 40 to 65 years, and participants 
with known clinical CVD were excluded from the study. 
The specific study inclusion and exclusion criteria are listed in Table 1. Besides the criteria 
described above, additional exclusion criteria referred to contraindications for computed tomography 
(CT) testing or other study procedures, active cancer, and inability to provide consent for participation. 
Both prevalent CVD and the rest of inclusion and exclusion criteria were determined exclusively on the 
basis of self-reported information provided by the study participants; no attempts were made to 
validate the participant’s response(s) as this is the standard set by prior cohort studies.   
Research Ethics 
The study protocol was reviewed and approved by the Institutional Review Board (IRB) of BHSF. 
All study procedures adhered to the principles included in the Declaration of Helsinki.29 All participants 
provided written informed consent prior to study entry, and potential participants unable to 
comprehend and sign an informed consent form were excluded. The same was true for potential 
participants who failed to provide written consent for whichever reason. As BHSF is a sponsor of this 
study, additional strategies with IRB guidance were implemented to minimize potential ethics risks (e.g., 
privacy) associated with employee-participants. 
Recruitment Strategy 
The principal investigator and research staff were responsible for creating recruitment strategies 
which complied with both BHSF and federal regulations. The purpose, rationale, and design of the study 
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was publicized to targeted groups in Baptist Health and community members of South Florida (table 2). 
The efforts included mailings of letters and brochures, posters, newspaper and radio advertisement as 
well as detailed on the study website (MiamiHeartStudy.net) followed by personal contacts via 
telephone, email, or in person. The marketing and advertising materials tailored to meet unique aspects 
of the source population and recruitment strategy were submitted to the IRB for approval prior to 
implementation tailored to meet unique aspects of the source population and recruitment strategy.   
Baseline Data Collection 
The baseline study examination took place between May 2015 and September 2018. As shown 
in Table 3, the baseline study examination included 1) a detailed assessment of self-reported 
cardiovascular risk factors, including demographic characteristics, medical history, medication use, 
lifestyle characteristics, and psychosocial factors; 2) a detailed physical exam, which included vitals and 
anthropometric measurements; 3) blood sampling for determination of biomarker assessment, 
advanced “omics” and biobanking; 4) assessment of subclinical atherosclerotic plaque, and vascular 
dysfunction; and 5) other tests, such as 12-lead electrocardiography, and assessment of pulmonary 
function. 
Study survey and questionnaires were administered via RedCap survey after online consent 
prior to clinic visit (Table 4). For participants unable to fill the questionnaires prior to their study visit, 
access to computers and to a paper version of the survey was provided at their clinic visit. Both English 
and Spanish versions were available  
Vitals: All participants had their temperature, heart rate, systolic and diastolic blood pressure, 
and respirations per minute taken and recorded using standard procedures. Specifically, for blood 
pressure, subjects were asked to sit quietly and rest for 5 minutes with their legs uncrossed, and an 
OMRON automatic blood pressure monitor (model BP710) was used. Three separate readings were 
taken at intervals of at least 1 minute 
Anthropometric measurements: Participants were weighed on a calibrated scale, without shoes 
and with all pockets emptied. The results were recorded to the nearest 0.2 kilograms. Height was 
measured in meters using the SECA 213 measuring system. The body mass index was computed as 
weight (kg) / (height [m] x height [m]). Waist circumference was measured at the top of the iliac crest 
using a K-E anthropometric tape positioned in a horizontal plane around the abdomen, applying tension 
to the tape to ensure it was snug yet without causing indentation to the skin. The measurement was 
performed at the end of a normal expiration. The hip circumference was measured at the level of the 
greatest girth—typically the level of the trochanters. Both measurements were made to the nearest 0.5 
cm. The waist to hip ratio was then computed as waist circumference (cm) / hip circumference (cm). 
Body fat percentage was measured using a hand-held body fat analyzer (OMRON Fat Loss Monitor 
Model HBF-306C). Subjects held the monitor with their arms straight out at a 90 degrees angle to their 
body. The device provided a percent fat estimate on the basis of measurements using the bioelectrical 
impedance method combined with inputs on the subjects’ age, sex, weight and height.  
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ECG: For electrocardiography, three 12-lead recordings were obtained using Welch Allyn 
standard digital 12-lead ECG. 
Spirometry: Spirometry measurements were obtained using the Welch Allyn spirometry 
machine. Welch Allyn disposable flow transducers were used and three measurements were made 
during rapid and forceful exhalation.  
Endothelial function: Peripheral arterial tone signal was used to measure, non-invasively, 
arterial tone changes in peripheral arterial beds, using the Itamar EndoPat 2000 system. Both the 
Reactive Hyperemia Index (RHI), a measure of endothelial function, and the Augmentation Index (AI), a 
measure of arterial stiffness, were measured. The test involved baseline measurement with the EndoPat 
probe on the index finger for 5 minutes. A blood pressure cuff was then applied on the non-dominant 
arm for next 5 minutes to occlude blood supply, and a recording is done during this phase. After 5 
minutes of occlusion to the non-dominant arm, the pressure is released. Once the blood flow is restored 
resulting in blood vessels to dilate, the EndoPat machine calculates the stiffness in the arterial walls. The 
vessel wall reactivity is the comparison of the pre-occlusion and post-occlusion blood flow and is 
reported as reactive hyperemia index. 
Carotid intima-media thickness (CIMT) was measured using the Panasonic CardioHealth Station 
automated carotid ultrasound device. Using a single transducer angle, fully automated CIMT 
measurements were recorded. The mean CIMT measurement is defined as the mean of 24 spatial 
measurements performed over a 1-cm region in the far wall of the common carotid artery. In addition, 
presence of any atherosclerotic coronary plaque was defined as any obvious focal luminal 
encroachment >1.00 mm. 
Pulse Wave Analysis: Pulse wave analysis and pulse wave velocity measurements were obtained 
using AtCor Medical SphygmoCor XCEL machine. It used a standard brachial cuff to measure brachial 
systolic and diastolic pressures and capture a brachial waveform. The brachial waveform was then 
analyzed by SphygmoCor to provide a central aortic waveform. Noninvasive central blood pressure 
measurements such as central aortic systolic blood pressure, central pulse pressure, and an aortic 
augmentation index (AIx) were also reported. Pulse wave velocity was measured using a carotid 
tonometer simultaneously with a leg cuff to capture blood pressure waveforms at the carotid and 
femoral sites. 
Coronary CT: In all participants, a non-contrast cardiac-gated CT scan for CAC testing was 
performed prior to conducting a contrast-enhanced, cardiac-gated CCTA. Both contrast and non-contrast 
scans were performed using GE Revolution (GE Healthcare) scans. Before the test, study participants 
received oral and/or intravenous β-blocker (metoprolol) as needed to achieve a heart rate of <75 beats per 
minute. Additionally, 0.4mg of sublingual nitroglycerine was given immediately before angiographic 
image acquisition. The radiation dose was estimated from the dose-length product multiplied by the 
conversion factor (0.014 mSv/mGy • cm). Assessment of 17 segment plaque presence/burden and 
classification was performed at a central core imaging lab.  
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Laboratory analyses and biobanking: In each participant, 97.5 ml of fasting blood were collected 
at baseline (approximately ~53 aliquots per participant) for serum, plasma and whole blood. Samples 
were tested for a wide range of biomarkers (Table 5). In addition, blood aliquots were bio-banked and 
maintained at -80°C for future ancillary analyses. One 7.5 ml SST vacutainer drawn is left at room 
temperature for 20-30 minutes for clotting before centrifugation at 3600xg for 15 minutes. After 
centrifugation, serum is removed from SST vacutainer. It is aliquoted in 2 ml Starstedt microtubes 
creating four aliquots. Six 10 ml red top vaccutainers are drawn and allowed to clot at room temperature 
before centrifugation. If a patient opted out of biobanking then only five red top vaccutainers are drawn. 
They are also centrifuged at 3600xg for 15 minutes. The serum is then aliquoted into 40 2ml Starstedt 
tubes with each tube containing 0.75 ml serum. One 4ml Na+ Heparin vacutainer is drawn and then 
centrifuged at 3600xg for 15 minutes within one hour of blood draw. It is then aliquoted in 0.75 ml 
volumes into 2ml Starstedt tubes creating 2 aliquot tubes. Two 10 ml ethylenediaminetetraacetic acid 
(EDTA) vacutainers are drawn which are also centrifuged at 3600xg for 15 minutes within one hour of 
blood draw. The serum is then aliquoted into 12 2 ml Starstedt tubes with each tube containing 0.75 ml 
serum. Additionally, three 2ml K2 EDTA tubes are drawn for every participant. If the subject opted out of 
genetic testing, then only one 2 ml K2 EDTA tube is drawn. These K2 EDTA tubes are not centrifuged 





          All MiHeart data are collected and stored using the Research Electronic Data Capture (REDCap) 
electronic data capture software, which is widely used for research purposes at Baptist Health South 
Florida and elsewhere. REDCap is a secure, web-based application designed to support data collection 
for research studies. Only authorized study personnel have access to the study data, and the study 
datasets undergo periodic quality control checks by the database administrator and study coordinators. 
Additionally, all study data undergo periodic audits by the IRB at Baptist Health South Florida. 
 
Results 
 MiHeart enrolled 2,459 participants free of clinical CVD at baseline, including 1,261 (51.3%) men 
and 1,198 women (48.7%). Mean age was 53 years, the majority of study participants were White 
(85.6%), and 1,166 (47.4%) were of Hispanic/Latino ethnicity.    
The baseline sociodemographic and clinical characteristics of the study population are 
summarized in Table 6. More than 72% participants were either overweight or obese, while only 3% 
were current smokers. Approximately 7% had diabetes, 33% hypertension, and 15% used statin therapy 
at baseline. Median 10-year estimated atherosclerotic CVD risk using the Pooled Cohort Equations was 
4%. Compared with 2010 US Census data for the population of Miami (Table 1), the MiHeart study 
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population had a similar proportion of women (50.2% in Miami vs. 48.7% in MiHeart), and a lower 
proportion of Hispanic/Latino participants (65% vs. 47.4%). Compared with the demographics of the 
BHSF workforce, the proportion of women was markedly lower in MiHeart, while the proportion of 
Hispanic/Latinos was identical.  
 
Discussion 
 MiHeart is a large, ongoing, community-based, prospective cohort study of men and women 
aged 40 to 65 years who underwent a comprehensive phenotyping of traditional and novel 
cardiovascular risk factors, and diverse measurements of subclinical CVD. So far, to the best of our 
knowledge no large US prospective study has conducted a baseline CCTA assessment of the study 
population. MiHeart will provide a comprehensive evaluation of coronary plaque burden, subtypes, 
morphology, and vulnerability features in a community-based primary prevention cohort. These unique 
data from MiHeart will generate invaluable opportunities for groundbreaking research, enhancing our 
understanding of the natural history of CVD, the early stages of subclinical atherosclerosis, and the key 
underlying social, lifestyle and metabolic determinants.  
Prior landmark multi-ethnic cardiovascular cohorts such as the Multi-Ethnic Study of 
Atherosclerosis (MESA) or the Dallas Heart Study restricted their baseline assessment of coronary 
atherosclerosis to CAC.30–34 While CAC has demonstrated an excellent performance as a tool for further 
risk assessment in middle-aged individuals, whether the inability of non-contrast CT to detect non-
calcified plaque may limit its performance for risk prediction in younger adults, or whether a CAC score 
of zero may be less reassuring in this age group, remain unclear. It must be noted, however, that as of 
2021 the Agatston score, which was developed in 1990,35 has not been replaced by more modern 
measurements of plaque morphology or high-risk plaque features that can be measured with CCTA.18,22–
27 
MiHeart is a natural extension of existing cohorts, like MESA, which with more than 2,000 
publications has provided significant insights into the role of atherosclerosis imaging with CAC in guiding 
risk assessment and subsequent management mostly in middle-aged individuals.13–15,30–34 In spite of 
notable improvements in our understanding of the significance of atherosclerotic processes to date, in 
studies such as MESA, the role of non-invasive atherosclerotic plaque imaging tools has been restricted 
to an older subset of middle-aged individuals (usually aged 60 and above) and limited to CIMT and 
CAC.30–34 With advances in contrast enhanced multi-detector CT we have now significantly improved our 
ability to non-invasively obtain comprehensive information not only based on presence and burden, but 
also accounting for characteristics of coronary atherosclerotic plaques to form the basis of more 
advanced and contemporary indices of atherosclerotic disease assessment. MiHeart will be the first 
prospective multi-ethnic population-based cohort study of a younger population free of clinical CVD 
undergoing CCTA testing. This information will provide detailed insights on burden and plaque 
characteristics in earlier stages of atherosclerosis, along with the characterization of biomarkers that can 
identify high-risk individuals at an early stage. This has been relatively unexplored, particularly in 
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populations of (relatively) younger asymptomatic individuals (age 40-65 years) who may initially be 
considered at low-risk for cardiovascular events. 
Furthermore, with robust core lab based plaque assessment protocols, strict quality control 
measures and leveraging our stored biobank, MiHeart will further our understanding of the 
pathogenesis of atherosclerosis and other CVDs by (1) providing more accurate and quantifiable 
measures of subclinical CVD among (younger) middle-aged asymptomatic individuals; (2) characterizing 
earliest changes of atherosclerosis (when it may be subjected to interventions that disrupt the natural 
history and progression of the disease); prior to clinical manifestation; (3) allowing for discovery and 
validation of accurate and reliable biomarkers for early atherosclerotic disease so that they can be 
rapidly translated into everyday clinical practices and (4) allowing comparisons among groups at 
different levels of risk that may provide clues to pathogenesis.  
Another distinguishing feature is that MiHeart enrolled participants from most racial/ethnic 
groups in the US, including a large representation of the two largest groups—non-Hispanic Whites 
(NHWs) and Hispanics/Latinos.36 While NHWs have been included in numerous American cardiovascular 
studies since the landmark Framingham study,37 prospective cardiovascular research in 
Hispanics/Latinos has been more limited. With a population of 60.6 million in 2019, Hispanics/Latinos 
have become the largest minority group in the United States.36,38 With evidence of increasing burden of 
ASCVD risk factors among Hispanics/Latinos in the US,39,40 there is a need to better understand the key 
determinants of disease in this large, rapidly growing demographic group. MiHeart will generate very 
important insights on the early stages of atherosclerosis in a large, rapidly growing group in the US. 
 
Limitations 
Some potential challenges are worth discussing. First, compared to the racial/ethnic distribution 
of the US population, NHWs are underrepresented in MiHeart. Although this is consistent with the 
specific demographic characteristics of the Greater Miami Area (according to the 2010 US Census,41 only 
12% were NHWs, and researchers will have to account for the large proportion of Hispanic/Latino 
participants in MiHeart when drawing conclusions to the general US population from analyses not 
stratified by race/ethnicity. This may have implications for risk factor and plaque burden findings, as well 
as for their prognostic implications. Second, follow-up is initially planned to last only 5 years. However, 
there are ongoing efforts to secure additional funding to further extend the follow-up to 10 or more 
years. Also, efforts are also ongoing to fund a second, repeat CCTA measurement over time, which will 
allow to evaluate changes in plaque characteristics over time and define the key baseline determinants.  
 
Conclusion 
 MiHeart at BHSF will provide important new information about the pathophysiology of early 
subclinical disease development and its role in clinical CVD. The study has the potential to identify new 
risk factors, discover/validate novel biomarkers (metabolic and genetic) for the earliest and highest risk 
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plaques in younger asymptomatic individuals and, therefore, increase the ability to predict CVD and, 
ultimately, to design new interventions to prevent CVD. The multiethnic composition of the study 
population is a major strength of the study, allowing comparisons that may provide unique insights 
about new risk factors and subclinical disease, and opening the possibility of tailoring prevention efforts 
according to ethnic differences in disease processes. The results of the study will be applicable to clinical 
practice by identifying noninvasive subclinical disease measures that best predict risk and by suggesting 
new approaches to interventions that prevent progression of subclinical disease and its transformation 
to clinical disease. Findings may be directly applicable to clinical practice, may be used to design clinical 
trials or optimize interventions, and/or may lead to research resulting in new methods of intervention. 
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FIGURE LEGENDS  
Figure. Study timeline, Miami Heart Study.  
Abbreviations: CVD = cardiovascular disease 
 
Central Illustration. Study design, Miami Heart Study. 
 




Table 1. Study participant enrollment criteria, Miami Heart Study. 
Inclusion Criteria  
 Current full time/part-time employees of BHSF (occupational cohort) or resident of 
Greater Miami Area for at least six months (community cohort) 
 Age 40 to 65 years 
 Asymptomatic individuals free of any known clinically overt cardiovascular disease  
 Able to comprehend and sign an informed consent form 
Exclusion Criteria 
 Prior history of major cardiovascular events (angina, myocardial infarction, prior 
coronary revascularization) 
 History of cerebrovascular disease including stroke and transient ischemic attack 
 History of peripheral arterial disease 
 History of either diagnosis or surgery for abdominal aortic aneurysm 
 History of heart failure 
 Weight greater than 350 lbs 
 Any contraindication for computed tomography scanning or non-iodinated contrast 
(BHSF West Kendall computed tomography angiography Imaging 
Screening/Prerequisites/Methods) 
 Active treatment for cancer 
 Currently pregnant, breastfeeding, seeking to become pregnant, or suspect they may 
be pregnant. 
 Patients who do not agree to provide informed consent 
 
Potential participants who responded “Don’t know” to questions about medical conditions were not be 
considered ineligible. 
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Abbreviations: BHSF = Baptist Health South Florida 
 
Table 2. Recruitment strategies, Miami Heart Study. 
BHSF Employees 
A. Study information was placed on the BHSF intranet site, Employee Newsletter, 
Pineapple Press, Leaders Edge, and The Wellness Advantage and Research Matters 
newsletter 
B. Monthly email blasts from the Wellness Prevention distribution group sent to all 
BHSF employees 
C. Advertising materials distributed at Town Hall meetings at BHSF entities 
D. Lunch & Learn Presentations throughout BHSF entities by the principal investigator 
and coinvestigators  
E. Study team members with designated table at Wellness Advantage Fairs & 
Programs, BHSF CME conferences/symposiums, BHSF community events and 
BHSF leadership retreats   
F. Study team members partnered with BHSF Employee Advisory Group and the 
Employee Activity Committee at scheduled employee events and activities to recruit 
employees 
G. Physician Relations newsletters & Medical Memo  
H. Wellness Advantage fitness and education programs for employees 
I. Digital signage (advertisement on entity televisions) throughout all BSHF entities 
Non BHSF employees/Community members 
A. Community outreach programs such as the West Kendall Initiative 
B. Web postings (internet, baptisthealth.net) with link to the study website 
MiamiHeartStudy.com. Study information was also placed on Centerwatch.com and 
ClinicalTrials.gov 
C. Study team members utilized the following BHSF publications: Resource, Baptist 
Salud & Women’s Health Resource Newsletter 
D. BHSF Community Health’s education, screening and exercise programs as well as 
the “Healthy West Kendall Initiative” 
E. West Kendall Baptist Hospital community events throughout the year to 
disseminate study information  
F. Partner with BHSF physician relations representative throughout BHSF entities to 
post recruitment materials in physician offices 
G. Subject & Physician Recruitment Letters 
H. Social Media: Facebook, Twitter, Instagram 
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I. Posting & distributing recruitment materials throughout local pharmacies 
and grocery stores as well as local gyms & fitness centers in the greater Miami area 
J. Radio ads in English/Spanish 
K. Movie theater story board – English only  
 
Abbreviations: BHSF = Baptist Health South Florida; CME = continued medical education 
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Table 3. Schedule of procedures and data collection in the Miami Heart Study. 
Procedure Baseline Yearly Follow-up 
Enrollment and informed consent X  
Lifestyle, diet and behavior questionnaires X  
Vitals X  
Anthropometric measurements X  
12-lead ECG X  
Spirometry X  
Endothelial function assessment X  
Carotid ultrasound/Intima-media thickness measurement X  
CT coronary calcium scoring/CT angiography X  
Laboratory analysis X  
Biobanking X  
Pulse wave analysis X  
Follow-up for clinical events  X 
 
Abbreviations: CT = computed tomography; ECG = electrocardiogram  
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Table 4. Baseline questionnaires and surveys, Miami Heart Study. 
Questionnaire Description/Items Assessed 
Anxiety General Anxiety Disorder7-item scale (GAD-7) 
Demographics Age, Gender, Race, Ethnicity, Language, Education, 
Employment, Marital Status, Socio-economic status 
Depression Modified Patient Health Questionnaire (PHQ-9) 
Diet Food Frequency Questionnaire, Food Access Survey 
Lung Function Assessment of Coughing, Wheezing, Shortness of Breath, 
Inhibition of ADL’s 
Medical & Family History Conditions related to heart and vascular disorders, lung and 
breathing related disorders, gastrointestinal disorders, 
endocrine, hematologic, mental health, eye, rheumatologic & 
dermatologic disorders, reproductive history, cancer, family 
medical history 
Medication History Prescription and non-prescription medication use, 
vitamin/dietary supplements and alternative medications 
Mental Health Continuum Feelings of happiness, confidence, satisfaction with life, and 
belonging 
Mindfulness Assessment of spiritual and mental awareness and presence 
Physical Activity Current physical activity including work, household, leisure, 
sport related activity, sedentary behavior 
Sleep Snoring, Tiredness (Berlin Questionnaire), Daytime sleepiness 




Past and current cigarette use, ever use of cigars and pipes, 
use of modified harm-reduction tobacco products, exposure 
to secondhand smoke. Current consumption of caffeinated 
products on a daily basis 
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Alcohol Use Usual intake and drinking patterns. 
Social Support Available and perceived social support, emotional support, 
help with chores, someone who will listen, etc 
Spirituality Feelings of peace, purpose, finding strength and comfort in 
faith (FACIT-12) 
Stress Perceived stress scale, stress in the workplace 
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Table 5. Baseline laboratory analyses, Miami Heart Study. 
Group of measurements Specific measurements 
Cardiac Enzymes  N-terminal pro b-type natriuretic peptide (NT-ProBNP) 
(pg/mL) 
Hemostasis and Fibrinolysis  D-Dimer (mcg/mL) 
Inflammation  High sensitivity C-reactive protein (hs-CRP) (mg/L) 
 Interleukin-2 (IL-2) (pg/mL) 
 Interleukin-6 (IL-6) (pg/mL) 
 Tumor Necrosis Factor (TNF) alpha (pg/mL) 
Diabetes  Whole Blood Hemoglobin A1c (HbA1c) 
 Serum Insulin (uIU/mL) 
 Free Fatty Acid (mmol/L) 
Endothelial Cell Function  Homocysteine (umol/L) 
Lipids  Cholesterol (mg/dL), Total, High-Density Lipoprotein 
(HDL), Low-Density Lipoprotein (LDL), Triglycerides 
 Ion Mobility: Lipid size, distribution, subclasses 
 Apolipoprotein B (ApoB) (mg/dL) 
 Lipoprotein (a) (Lp[a]) (nmol/L) 
 Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) 
(nmol/min/mL) 
Nutrition  Omega-3 and Omega-6 Fatty Acids 
Genetics  ApoE Genotype 
 9p21 Genotype 
 KIF6 Genotype 
 LPA Intron 25 
 4q25 A-Fib genotype 
Obesity/Metabolism  Leptin (ng/mL) 
 Adiponectin (mcg/mL) 
Renal Function  Cystatin-C (mg/L) 
 Aldosterone (ng/dL) 
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Sex Hormones  Testosterone, Free (pg/mL) &Total (ng/dl),  
 Dehydroepiandrosterone (ng/dL) 
 Estradiol (pg/mL) 
 Sex Hormone Binding Globulin (nmol/L) 
Vitamins and Minerals  1, 25 Dihydroxy Vitamin D (pg/mL) 
 25-Hydroxyvitamin D [25(OH)D] (ng/mL) 
 Thyroid Stimulating Hormone (TSH) (mIU/L) 
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Table 6. Baseline characteristics of the study population, Miami Heart Study. 
 
 MiHeart Study (N=2,459) 
Demographics  
     Age, years 53.35 (6.78) 
     Women 1,198 (48.7%) 
     Race  
          White 2,104 (85.6%) 
          Black 94 (3.8%) 
          Asian 74 (3%) 
          Other 186 (7.6%) 
     Ethnicity  
          Hispanic/Latino 1,166 (47.4%) 
          Not Hispanic/Latino 1,255 (51%) 
Other cardiovascular risk factors  
     Body mass index, kg/m2 28.45 (5.29) 
     Body mass index categories  
          Normal weight 679 (27.6%) 
          Overweight 991 (40.3%) 
          Obesity 789 (32.1%) 
     Family history of CVD 707 (28.8%) 
     Family history of premature CVD 185 (7.5%) 
     Tobacco use  
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          Current smoker 75 (3.1%) 
          Former smoker 602 (24.5%) 
          Never smoker 1,782 (72.5%) 
     Diabetes 175 (7.1%) 
     Hypertension 808 (32.9%) 
     Hyperlipidemia 331 (13.5%) 
     Dyslipidemia 731 (29.7%) 
Baseline medication use  
     Statin use 371 (15.1%) 
     Aspirin use 569 (23.1%) 
Estimated ASCVD risk  
     10-Year Estimated ASCVD risk,* % 3.96 (4.16) 
 
*Using the Pooled Cohort Equations 
Results are presented as either number (%) or mean (standard deviation). 
Abbreviations: ASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease 
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